3/13
03:04 pm
tngx
Tango Therapeutics' (TNGX) Sees Cautious Analyst Optimism Following Earnings [Yahoo! Finance]
Low
Report
Tango Therapeutics' (TNGX) Sees Cautious Analyst Optimism Following Earnings [Yahoo! Finance]
3/11
04:35 pm
tngx
Wedbush Reaffirms Outperform Rating for Tango Therapeutics (TNGX) [Yahoo! Finance]
Low
Report
Wedbush Reaffirms Outperform Rating for Tango Therapeutics (TNGX) [Yahoo! Finance]
3/11
09:44 am
tngx
Tango Therapeutics (TNGX) had its price target raised by Mizuho from $19.00 to $20.00. They now have an "outperform" rating on the stock.
Medium
Report
Tango Therapeutics (TNGX) had its price target raised by Mizuho from $19.00 to $20.00. They now have an "outperform" rating on the stock.
3/9
09:03 am
tngx
Tango Therapeutics (TNGX) had its price target raised by Stifel Nicolaus from $15.00 to $24.00. They now have a "buy" rating on the stock.
Low
Report
Tango Therapeutics (TNGX) had its price target raised by Stifel Nicolaus from $15.00 to $24.00. They now have a "buy" rating on the stock.
3/9
04:04 am
tngx
Tango Therapeutics (TNGX) Soars 52% on Buy Reco [Yahoo! Finance]
Medium
Report
Tango Therapeutics (TNGX) Soars 52% on Buy Reco [Yahoo! Finance]
3/8
07:44 am
tngx
Tango Therapeutics (TNGX) Valuation Check After Strong Share Price Momentum And High P/S Multiple [Yahoo! Finance]
Medium
Report
Tango Therapeutics (TNGX) Valuation Check After Strong Share Price Momentum And High P/S Multiple [Yahoo! Finance]
3/7
02:59 am
tngx
Medium
Report
3/6
10:00 pm
tngx
Tango Therapeutics, Up 39% This Year, Surges Again On Another Cancer Pact [Yahoo! Finance]
Medium
Report
Tango Therapeutics, Up 39% This Year, Surges Again On Another Cancer Pact [Yahoo! Finance]
3/6
05:33 pm
tngx
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
3/6
04:08 pm
tngx
Tango Therapeutics: I'm Not Buying Into Latest Rally, Despite PRMT5 Promise [Seeking Alpha]
Low
Report
Tango Therapeutics: I'm Not Buying Into Latest Rally, Despite PRMT5 Promise [Seeking Alpha]
3/6
08:55 am
tngx
Tango Therapeutics (TNGX) had its price target raised by Wedbush from $15.00 to $19.00. They now have an "outperform" rating on the stock.
Low
Report
Tango Therapeutics (TNGX) had its price target raised by Wedbush from $15.00 to $19.00. They now have an "outperform" rating on the stock.
3/6
08:29 am
tngx
Tango Therapeutics (TNGX) had its price target raised by Guggenheim from $18.00 to $20.00. They now have a "buy" rating on the stock.
Low
Report
Tango Therapeutics (TNGX) had its price target raised by Guggenheim from $18.00 to $20.00. They now have a "buy" rating on the stock.
3/6
08:03 am
tngx
Tango Therapeutics (TNGX) had its price target raised by HC Wainwright from $13.00 to $27.00. They now have a "buy" rating on the stock.
Low
Report
Tango Therapeutics (TNGX) had its price target raised by HC Wainwright from $13.00 to $27.00. They now have a "buy" rating on the stock.
3/5
08:30 pm
tngx
Tango Therapeutics (TNGX) Hits All-Time High as Analyst Turns Bullish [Yahoo! Finance]
Low
Report
Tango Therapeutics (TNGX) Hits All-Time High as Analyst Turns Bullish [Yahoo! Finance]
3/5
08:07 pm
tngx
Tango Therapeutics (TNGX) had its "buy" rating reaffirmed by Jefferies Financial Group Inc..
Low
Report
Tango Therapeutics (TNGX) had its "buy" rating reaffirmed by Jefferies Financial Group Inc..
3/5
07:29 am
tngx
Tango Therapeutics GAAP EPS of -$0.29 beats by $0.03, revenue of $0M misses by $0.5M [Seeking Alpha]
High
Report
Tango Therapeutics GAAP EPS of -$0.29 beats by $0.03, revenue of $0M misses by $0.5M [Seeking Alpha]
3/5
07:00 am
tngx
Tango Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlights
High
Report
Tango Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlights
3/4
06:48 pm
tngx
Investment Firm Bets Big on TNGX Stock With $9.5 Million Purchase, According to Recent SEC Filing [Yahoo! Finance]
High
Report
Investment Firm Bets Big on TNGX Stock With $9.5 Million Purchase, According to Recent SEC Filing [Yahoo! Finance]
2/23
09:00 am
tngx
Tango Therapeutics (NASDAQ:TNGX) is now covered by analysts at Mizuho. They set an "outperform" rating and a $19.00 price target on the stock.
Medium
Report
Tango Therapeutics (NASDAQ:TNGX) is now covered by analysts at Mizuho. They set an "outperform" rating and a $19.00 price target on the stock.
2/18
07:00 am
tngx
Tango Therapeutics to Report Fourth Quarter 2025 Financial Results and Participate in Three Upcoming Investor Conferences
Medium
Report
Tango Therapeutics to Report Fourth Quarter 2025 Financial Results and Participate in Three Upcoming Investor Conferences
2/15
02:21 pm
tngx
Tango Therapeutics CEO Teases Pivotal Vopimetostat Trial, RAS Combo Data at Guggenheim Chat [Yahoo! Finance]
Low
Report
Tango Therapeutics CEO Teases Pivotal Vopimetostat Trial, RAS Combo Data at Guggenheim Chat [Yahoo! Finance]
2/6
09:47 am
tngx
Tango Therapeutics (NASDAQ:TNGX) had its price target raised by analysts at Guggenheim from $12.00 to $18.00. They now have a "buy" rating on the stock.
Medium
Report
Tango Therapeutics (NASDAQ:TNGX) had its price target raised by analysts at Guggenheim from $12.00 to $18.00. They now have a "buy" rating on the stock.
2/3
07:00 am
tngx
Tango Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
Medium
Report
Tango Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
1/28
05:49 pm
tngx
DUB Inhibitors Market to Witness Strong Expansion Across 7MM by 2040 Driven by the Launch of Novel Therapeutics | DelveInsight [Yahoo! Finance]
Medium
Report
DUB Inhibitors Market to Witness Strong Expansion Across 7MM by 2040 Driven by the Launch of Novel Therapeutics | DelveInsight [Yahoo! Finance]
1/9
01:46 pm
tngx
Does Tango Therapeutics' (TNGX) CEO Transition Clarify or Complicate Its Precision Oncology Roadmap? [Yahoo! Finance]
Low
Report
Does Tango Therapeutics' (TNGX) CEO Transition Clarify or Complicate Its Precision Oncology Roadmap? [Yahoo! Finance]